XNAS
CRMD
Market cap572mUSD
Oct 08, Last price
7.32USD
1D
0.55%
1Q
-12.86%
Jan 2017
-4.31%
IPO
-51.20%
Name
CorMedix Inc
Chart & performance
P/E
3.52
P/S
1.84
EPS
2.08
Div yield, %
—
Shrs. gr., 5y
22.97%
Rev. gr., 5y
319.75%
Revenues
312m
+617.03%
Net income
163m
P
CFO
175m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Key people
Matthew T David
Chief Financial Officer, Executive Vice President · since 2020
Phoebe Mounts
Executive Vice President, General Counsel, Head of Regulatory, Compliance and Legal · since 2019
Randy Milby
Chief Executive Officer, Director · since 2013
Antony E. Pfaffle
Chief Scientific Officer, Director · since 2014
Janet M. Dillione
Independent Director · since 2015
Independent Director · since 2019
Independent Director · since 2017
Steven W. Lefkowitz
Independent Director · since 2014
Legal address
c/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
WILMINGTON, DE 19808
US
Headquarters
400 Connell Drive, Suite 5000
Berkeley Heights, NJ 07922
US
Berkeley Heights, NJ 07922
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||